Pier Capital’s Pacira BioSciences PCRX Stock Holding History

Pier Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-74,938	Closed	-$5.75M	–	125
2015 Q4	$5.75M	Buy	+74,938	New	+$4.24M	1%	60
2015 Q1	–	Sell	-34,084	Closed	-$3.02M	–	117
2014 Q4	$3.02M	Sell	34,084 -31,029	-48%	-$2.94M	0.45%	96
2014 Q3	$6.31M	Sell	65,113 -30,235	-32%	-$2.94M	1.01%	55
2014 Q2	$8.76M	Sell	95,348 -37,109	-28%	-$2.83M	1.24%	16
2014 Q1	$9.27M	Sell	132,457 -1,424	-1%	-$96.9K	1.19%	14
2013 Q4	$7.7M	Sell	133,881 -64,798	-33%	-$3.41M	1.03%	44
2013 Q3	$9.55M	Sell	198,679 -35,450	-15%	-$1.29M	1.35%	8
2013 Q2	$6.79M	Buy	+234,129	New	+$6.77M	1.04%	47

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Pier Capital's PCRX Position: Q1 2016 in Review

Pier Capital sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 74,938 shares — an estimated $5.75M sold.

Pier Capital first reported a position in PCRX in Q2 2013 and held it in 8 quarters. The position peaked at $9.55M in Q3 2013. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

Pier Capital reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
Pier Capital sold 74,938 Pacira BioSciences shares in Q1 2016, an estimated $5.75M.
Pier Capital first reported a position in Pacira BioSciences in Q2 2013 and held it in 8 quarters.
Pier Capital's Pacira BioSciences position peaked at $9.55M in Q3 2013.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Pier Capital's 13F filing for Q1 2016, filed 5 May 2016.